Clinical Trial Update: Synbiotic Compound to Reduce Symptoms of Schizophrenia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating a synbiotic compound to reduce symptoms of schizophrenia and schizoaffective disorder is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizoaffective Disorder
• Schizophrenia

Drugs mentioned

• Synbiotic Compound

Snippet

Sponsor: Sheppard Pratt Health System | Conditions: Schizophrenia, Schizoaffective Disorder | Phase 2 | Status: RECRUITING